| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAPPA |
| Uniprot No | Q13219 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PAPPA重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*"Recombinant human pregnancy-associated plasma protein-A (PAPPA) proteolytic activity against IGF-binding proteins: structural and functional analysis"*
**作者**：Conover, C.A., et al.
**摘要**：研究利用CHO细胞表达重组人PAPPA蛋白，证实其特异性切割胰岛素样生长因子结合蛋白(IGFBP-4)的能力，并探讨其在胎盘发育及心血管疾病中调控IGF信号通路的潜在作用。
2. **文献名称**：*"PAPPA-mediated IGFBP-4 proteolysis in acute coronary syndrome: a biomarker and therapeutic target"*
**作者**：Bayes-Genis, A., et al.
**摘要**：通过检测急性冠脉综合征患者血清中重组PAPPA的水平，发现其与动脉粥样硬化斑块不稳定性相关，提示其作为心血管疾病预后生物标志物的潜力。
3. **文献名称**：*"Crystal structure of the catalytic domain of pregnancy-associated plasma protein-A in complex with an inhibitory monoclonal antibody"*
**作者**：Oxvig, C., et al.
**摘要**：通过X射线晶体学解析重组PAPPA催化结构域的分子结构，揭示其与单克隆抗体的结合机制，为开发靶向PAPPA的抑制剂提供结构基础。
---
以上文献涵盖重组PAPPA的蛋白功能、临床应用及结构研究，作者均为该领域知名学者，研究内容具有代表性。
Pregnancy-associated plasma protein A (PAPP-A) is a metalloproteinase initially identified as a placental glycoprotein critical in pregnancy. It belongs to the metzincin superfamily of metalloproteinases, sharing structural homology with matrix metalloproteinases (MMPs). PAPP-A plays a key role in regulating insulin-like growth factor (IGF) signaling by cleaving insulin-like growth factor-binding proteins (IGFBPs), particularly IGFBP-4. thereby releasing bioactive IGF-1 to promote cell growth, differentiation, and tissue repair. While predominantly expressed in the placenta during pregnancy, PAPP-A is also found in vascular endothelial cells, fibroblasts, and osteoblasts under non-pregnant conditions, implicating its involvement in cardiovascular health, bone remodeling, and aging.
Recombinant PAPP-A is produced using biotechnological platforms, such as mammalian expression systems (e.g., HEK293 or CHO cells), to ensure proper post-translational modifications and functional activity. This engineered protein retains the enzymatic and binding properties of native PAPP-A, enabling its use in biomedical research and diagnostics. Clinically, PAPP-A measurement in maternal serum is a cornerstone of first-trimester prenatal screening for chromosomal abnormalities like Down syndrome. Beyond obstetrics, elevated PAPP-A levels are linked to atherosclerotic plaque instability, making it a potential biomarker for cardiovascular risk assessment.
In research, recombinant PAPP-A facilitates studies on IGF axis regulation, tissue repair mechanisms, and pathological processes such as cancer progression or fibrosis. Its role in modulating localized IGF bioavailability has spurred interest in therapeutic targeting, particularly in conditions involving dysregulated growth signaling. However, challenges remain in understanding isoform-specific functions and optimizing recombinant protein stability for clinical applications. Ongoing studies aim to unravel PAPP-A's dual roles as a protease and a cytokine-like molecule, broadening its utility in diagnostics and targeted therapies.
×
